The only way to manage neurodegeneration in MS is to prevent it with effective anti-inflammatory therapy: Yes

Abstract

Get full access to this article

View all access options for this article.

References

Fox

. Primary neuroprotection: The Holy Grail of multiple sclerosis therapy. Neurology 2010; 74: 1018–1019.

Tallantyre

Bø

Al-Rawashdeh

. Clinico- pathological evidence that axonal loss underlies disability in progressive multiple sclerosis. Mult Scler 2010; 16: 406–411.

Trapp

Peterson

Ransohoff

. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278–285.

Frischer

Bramow

Dal-Bianco

. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009; 132: 1175–1189.

Centonze

Muzio

Rossi

. Inflammation triggers synaptic alteration and degeneration in experimental auto-immune encephalomyelitis. J Neurosci 2009; 29: 3442–3452.

Recks

Addicks

Kuerten

. Spinal cord histo-pathology of MOG peptide 35-55-induced experimental autoimmune encephalomyelitis is time- and score-dependent. Neurosci Lett 2011; 494: 227–231.

Al-Izki

Pryce

Jackson

. Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis. Mult Scler 2011; 17: 939–948.

Fisniku

Brex

Altmann

. Disability and T2 MRI lesions: A 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008; 131 (Pt 3): 808–817.

Brown

Kirby

Skedgel

. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? Neurology 2007; 69: 1498–1507.

10.

Coles

Compston

DAS

Selmaj

. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008; 359: 1786–1801.

11.

Choi

Howell

Carassiti

. Meningeal in-flammation plays a role in the pathology of primary progressive multiple sclerosis. Brain 2012; 135 (pt 10): 2925–2937.